RA
VIVO

Royce & Associates’s Meridian Bioscience Inc VIVO Stock Holding History

Royce & Associates’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-169,169
Closed -$5.33M – 988
2022
Q3 		$5.33M Sell
169,169
-1,508,085
-90% -$48.8M 0.06% 433
2022
Q2 		$51M Sell
1,677,254
-340,119
-17% -$9.2M 0.53% 35
2022
Q1 		$52.4M Sell
2,017,373
-178,477
-8% -$4.25M 0.44% 39
2021
Q4 		$44.8M Buy
2,195,850
+63,267
+3% +$1.21M 0.33% 59
2021
Q3 		$41M Buy
2,132,583
+90,084
+4% +$1.8M 0.31% 68
2021
Q2 		$45.3M Buy
2,042,499
+1,219,795
+148% +$25.9M 0.31% 69
2021
Q1 		$21.6M Buy
822,704
+147,870
+22% +$3.52M 0.15% 224
2020
Q4 		$12.6M Buy
674,834
+349,259
+107% +$6.52M 0.1% 311
2020
Q3 		$5.53M Buy
325,575
+247,757
+318% +$4.82M 0.06% 447
2020
Q2 		$1.81M Buy
77,818
+1,880
+2% +$27.2K 0.02% 686
2020
Q1 		$638K Buy
75,938
+20,560
+37% +$173K 0.01% 800
2019
Q4 		$541K Sell
55,378
-77,627
-58% -$729K ﹤0.01% 878
2019
Q3 		$1.26M Buy
133,005
+55,693
+72% +$587K 0.01% 779
2019
Q2 		$918K Sell
77,312
-1,449
-2% -$17.5K 0.01% 847
2019
Q1 		$1.39M Sell
78,761
-63,715
-45% -$1.06M 0.01% 816
2018
Q4 		$2.47M Sell
142,476
-5,223
-4% -$89.1K 0.02% 663
2018
Q3 		$2.2M Buy
147,699
+709
+0.5% +$11K 0.02% 808
2018
Q2 		$2.34M Buy
146,990
+448
+0.3% +$6.68K 0.02% 798
2018
Q1 		$2.08M Sell
146,542
-101
-0.1% -$1.5K 0.01% 840
2017
Q4 		$2.05M Sell
146,643
-5,107
-3% -$74.8K 0.01% 842
2017
Q3 		$2.17M Sell
151,750
-6,144
-4% -$87.8K 0.01% 811
2017
Q2 		$2.49M Hold
157,894
– – 0.02% 791
2017
Q1 		$2.18M Buy
157,894
+40,966
+35% +$573K 0.01% 834
2016
Q4 		$2.07M Buy
116,928
+68,628
+142% +$1.21M 0.01% 817
2016
Q3 		$932K Hold
48,300
– – 0.01% 936
2016
Q2 		$942K Hold
48,300
– – 0.01% 926
2016
Q1 		$995K Hold
48,300
– – 0.01% 926
2015
Q4 		$991K Sell
48,300
-5,300
-10% -$102K 0.01% 938
2015
Q3 		$917K Sell
53,600
-85,700
-62% -$1.57M ﹤0.01% 977
2015
Q2 		$2.6M Sell
139,300
-75,500
-35% -$1.4M 0.01% 884
2015
Q1 		$4.1M Sell
214,800
-54,700
-20% -$1.01M 0.02% 786
2014
Q4 		$4.44M Buy
269,500
+75,500
+39% +$1.3M 0.02% 807
2014
Q3 		$3.43M Buy
194,000
+177,900
+1,105% +$3.5M 0.01% 893
2014
Q2 		$332K Sell
16,100
-2,100
-12% -$43.2K ﹤0.01% 1269
2014
Q1 		$397K Hold
18,200
– – ﹤0.01% 1250
2013
Q4 		$483K Sell
18,200
-1,400
-7% -$34.4K ﹤0.01% 1236
2013
Q3 		$464K Buy
19,600
+14,400
+277% +$336K ﹤0.01% 1248
2013
Q2 		$112K Buy
+5,200
New +$112K ﹤0.01% 1324

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates's VIVO Position: Q4 2022 in Review

Royce & Associates sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 169,169 shares — an estimated $5.33M sold.

Royce & Associates first reported a position in VIVO in Q2 2013 and held it in 38 quarters. The position peaked at $52.4M in Q1 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

  • Royce & Associates reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
  • Royce & Associates sold 169,169 Meridian Bioscience Inc shares in Q4 2022, an estimated $5.33M.
  • Royce & Associates first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 38 quarters.
  • Royce & Associates's Meridian Bioscience Inc position peaked at $52.4M in Q1 2022.
  • 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Royce & Associates's 13F filing for Q4 2022, filed 13 Feb 2023.